IPO Archives

News and Trends 7 Sep 2017

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Nucana Biomed has filed for a Nasdaq IPO in which it expects to raise up to $115M (€96M) to support the progression of its oncology pipeline. Nucana Biomed, a biotech based in Edinburgh, specializes in using phosphoramidate chemistry to upgrade nucleoside analogs, a common form of chemotherapy drugs. With its pipeline reaching late stages of […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

destiny pharma new antibiotics mrsa london stock1

News and Trends 4 Sep 2017

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Destiny Pharma has started trading on the London Stock Exchange to support its search for new antibiotics that can fight resistant bacteria like MRSA. Destiny Pharma, based in Brighton, UK, has entered the AIM market of the London Stock Exchange with an initial placement of £15.3M (€16.7M), which put its starting market cap at £65.4M […]

September 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 9 Aug 2017

Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO

After announcing its intentions last month, Zealand Pharma has gone public in the US to fund its diabetes clinical trials. Zealand Pharma, a Glostrup-based biotech focused on peptide development for diabetes, has been public on the Danish Aktieselskabet exchange since 2011, and since then its share price has risen by 50%. After filing for an American […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 10 Jul 2017

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […]

July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 29 Jun 2017

Video: Questions about Biotech Capital Markets? Kempen & Co have Answers

In our first Refresh expert track presentation the audience had the chance to learn about the life sciences capital market, ask questions they had never dared to ask and discover the top five facts on the life sciences capital markets! With its strong focus on the life sciences and healthcare industry, the investment bank Kempen & […]

June 29, 2017 - 2 minutesmins - By External Contributor

argenx llama antibody immuno oncology IPO

News and Trends 22 May 2017

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […]

May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Apr 2017

Galapagos Shoots Past its IPO in a New Public Round of €315M

After its record €277 IPO on Nasdaq in 2015, Galapagos announced the pricing of its new US public offering at a massive €315M ($338M). Galapagos is clinging to its position as one of the biggest biotechs in Europe. While the Belgian biotech is currently pushing its rheumatoid arthritis candidate filgotinib through Phase III, the new US public offering could give […]

April 19, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 14 Mar 2017

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Avantium has gone public and raised €103M on Euronext Amsterdam and Euronext Bruxelles with Sofinnova Partner as the main shareholder. Avantium, a spin-off from Shell, is developing renewable bioplastics made 100% from plant-based materials with the support of big partners such as Coca-Cola or Danone, for which the Dutch biotech is developing sustainable PlantBottles and yogurt cups, […]

March 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Mar 2017

Swedish Oncology Biotech makes a Large IPO for its Peptides

The Swedish company Oncopeptides raised €68M with its IPO on Nasdaq Stockholm, which will allow the company to push their compound into phase III trials. Oncopeptides was founded in 2000 and is focused on the development of its lead compound Ygalo. After the company started a Phase II trial in patients with late stage relapsed and refractory multiple […]

March 1, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 17 Feb 2017

UPDATE: British Biotech Investment Company goes Public with €117M

UPDATE (17/02/2017): Arix Bioscience announced that it has successfully raised £100M (€117) in an oversubscribed IPO on the London Stock Exchange. Originally published on 02/02/2017 Arix Bioscience is getting ready for an IPO that could reach up to €117M (£100M). The funds will be directed at small life science companies. Arix Bioscience is a ‘global healthcare and life […]

February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Feb 2017

French Biotech gets a Boost in the NASH Race with a Successful IPO

Inventiva has completed an IPO on Euronext Paris raising €48M that will support the advancement of its pipeline, which includes big indications such as NASH. Inventiva, a drug discovery company from France, is the protagonist today of a successful biotech IPO on Euronext Paris despite the financial difficulties of past years. The company has raised €48M, which will […]

February 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

lysogene ipo euronext paris e1486638993948

News and Trends 9 Feb 2017

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Lysogene has raised €22.6M from its IPO on Euronext Paris that will contribute to the completion of clinical trials to treat the rare genetic diseases. Karen Aiach, CEO of Lysogene, started the company back in 2009 to develop a life-saving treatment for her daughter Ornella with Sanfilippo A. This rare genetic disease severely affects the nervous system of […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

IPO

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

British Biotech Developing New Antibiotics Enters the London Stock Exchange

Danish Diabetes Biotech Rakes in $75M on NASDAQ in American IPO

Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq

Video: Questions about Biotech Capital Markets? Kempen & Co have Answers

UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II

Galapagos Shoots Past its IPO in a New Public Round of €315M

Huge Successful €103M IPO for the Next European Leader in Bioplastics

Swedish Oncology Biotech makes a Large IPO for its Peptides

UPDATE: British Biotech Investment Company goes Public with €117M

French Biotech gets a Boost in the NASH Race with a Successful IPO

Gene Therapy Biotech Founded to Save the CEO’s Daughter Goes Public in France

Subscribe to our newsletter to get the latest biotech news!

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments

The biggest biotech funding rounds in February 2025

Grab your free report on 3D organoids and explore their future potential

World Cancer Day: trends in cancer therapeutics to look forward to in 2025

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!